We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst ...

Regeneron Pharmaceuticals recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with ...

We think investors are encouraged by the vagueness of the order and the significant room for negotiations. We sell different types of products and services to both investment professionals and ...

Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REGN. Sanofi plans $20 billion US investment by 2030 to expand R&D and ...

New Paltz High School senior Joseph Birnbaum was named a scholar in the Regeneron Science Talent Search (STS) for his groundbreaking research on wildfire intensity and its effects on the ...

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other checkpoint inhibitors.

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

ready to represent not only their educational institution but also Iraq and the Kurdistan Region at the prestigious Regeneron International Science and Engineering Fair (ISEF). These bright young ...